Drug‐coated balloons (DCBs) have emerged as an established treatment strategy for in‐stent restenosis (ISR) and selected de novo coronary lesions, particularly in small vessels. Unlike stents, DCBs deliver antiproliferative therapy without leaving a permanent intracoronary implant, thereby avoiding chronic inflammation, neoatherosclerosis, and late stent‐related complications. While the efficacy and safety of DCBs in ISR are well supported, data regarding their use in the setting of acute coronary syndrome (ACS) remain limited, where plaque rupture, thrombus burden, and heightened thrombotic risk raise unique procedural concerns. This review summarizes the available evidence evaluating the safety and efficacy of DCBs in ACS, including randomized controlled trials, observational studies, and registry data published over the past decade. We review outcomes across ACS subtypes, including ST‐segment elevation myocardial infarction (STEMI) and non‐ST‐segment elevation myocardial infarction (NSTEMI), and discuss lesion preparation strategies, thrombus management, bifurcation disease, and differences among drug‐coating technologies. Current evidence suggests that, in carefully selected patients with adequate lesion preparation and acceptable angiographic results, a DCB‐based strategy may offer outcomes comparable to contemporary drug‐eluting stents, while potentially reducing late device‐related complications and duration of dual antiplatelet therapy. Further prospective studies are needed to define optimal patient selection and procedural techniques, particularly in lesions with high thrombus burden.